220 related articles for article (PubMed ID: 18794123)
1. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.
Meyer AN; McAndrew CW; Donoghue DJ
Cancer Res; 2008 Sep; 68(18):7362-70. PubMed ID: 18794123
[TBL] [Abstract][Full Text] [Related]
2. A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.
Jin M; Yu Y; Qi H; Xie Y; Su N; Wang X; Tan Q; Luo F; Zhu Y; Wang Q; Du X; Xian CJ; Liu P; Huang H; Shen Y; Deng CX; Chen D; Chen L
Hum Mol Genet; 2012 Dec; 21(26):5443-55. PubMed ID: 23014564
[TBL] [Abstract][Full Text] [Related]
3. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum.
Lievens PM; Liboi E
J Biol Chem; 2003 May; 278(19):17344-9. PubMed ID: 12624096
[TBL] [Abstract][Full Text] [Related]
4. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCĪ³1/Src-mediated paxillin hyperphosphorylation.
Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
[TBL] [Abstract][Full Text] [Related]
5. The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation.
Meyer AN; Gastwirt RF; Schlaepfer DD; Donoghue DJ
J Biol Chem; 2004 Jul; 279(27):28450-7. PubMed ID: 15105428
[TBL] [Abstract][Full Text] [Related]
6. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
7. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
Chen J; Lee BH; Williams IR; Kutok JL; Mitsiades CS; Duclos N; Cohen S; Adelsperger J; Okabe R; Coburn A; Moore S; Huntly BJ; Fabbro D; Anderson KC; Griffin JD; Gilliland DG
Oncogene; 2005 Dec; 24(56):8259-67. PubMed ID: 16091734
[TBL] [Abstract][Full Text] [Related]
8. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
9. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.
Webster MK; D'Avis PY; Robertson SC; Donoghue DJ
Mol Cell Biol; 1996 Aug; 16(8):4081-7. PubMed ID: 8754806
[TBL] [Abstract][Full Text] [Related]
10. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
Paterson JL; Li Z; Wen XY; Masih-Khan E; Chang H; Pollett JB; Trudel S; Stewart AK
Br J Haematol; 2004 Mar; 124(5):595-603. PubMed ID: 14871245
[TBL] [Abstract][Full Text] [Related]
11. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
[TBL] [Abstract][Full Text] [Related]
12. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
Matsushita M; Kitoh H; Ohkawara B; Mishima K; Kaneko H; Ito M; Masuda A; Ishiguro N; Ohno K
PLoS One; 2013; 8(12):e81569. PubMed ID: 24324705
[TBL] [Abstract][Full Text] [Related]
13. Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.
Chen J; Williams IR; Lee BH; Duclos N; Huntly BJ; Donoghue DJ; Gilliland DG
Blood; 2005 Jul; 106(1):328-37. PubMed ID: 15784730
[TBL] [Abstract][Full Text] [Related]
14. The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor.
Bonaventure J; Horne WC; Baron R
FEBS J; 2007 Jun; 274(12):3078-93. PubMed ID: 17509076
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
Guan M; Zhu L; Somlo G; Hughes A; Zhou B; Yen Y
Anticancer Res; 2009 Jan; 29(1):1-9. PubMed ID: 19331127
[TBL] [Abstract][Full Text] [Related]
16. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
Qing J; Du X; Chen Y; Chan P; Li H; Wu P; Marsters S; Stawicki S; Tien J; Totpal K; Ross S; Stinson S; Dornan D; French D; Wang QR; Stephan JP; Wu Y; Wiesmann C; Ashkenazi A
J Clin Invest; 2009 May; 119(5):1216-29. PubMed ID: 19381019
[TBL] [Abstract][Full Text] [Related]
17. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
[TBL] [Abstract][Full Text] [Related]
18. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
Xin X; Abrams TJ; Hollenbach PW; Rendahl KG; Tang Y; Oei YA; Embry MG; Swinarski DE; Garrett EN; Pryer NK; Trudel S; Jallal B; Mendel DB; Heise CC
Clin Cancer Res; 2006 Aug; 12(16):4908-15. PubMed ID: 16914579
[TBL] [Abstract][Full Text] [Related]
19. Cell adaptation to activated FGFR3 includes Sprouty4 up regulation to inhibit the receptor-mediated ERKs activation from the endoplasmic reticulum.
Lievens PM; Zanolli E; Garofalo S; Liboi E
FEBS Lett; 2009 Oct; 583(19):3254-8. PubMed ID: 19761767
[TBL] [Abstract][Full Text] [Related]
20. HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
Ota S; Zhou ZQ; Romero MP; Yang G; Hurlin PJ
Hum Mol Genet; 2016 Oct; 25(19):4227-4243. PubMed ID: 27506979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
